ASPI Pengajuan SEC - ASP Isotopes Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1921865

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ASP Isotopes Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
September 2, 2025	EX-99.1	ASP Isotopes Issues Letter to Shareholders EXHIBIT 99.1 ASP Isotopes Issues Letter to Shareholders Washington, D.C., September 2, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman a
August 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
August 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
August 15, 2025	EX-99.1	ASP Isotopes Inc. and its Subsidiary, Quantum Leap Energy LLC, enter into a Memorandum of Understanding with Fermi America Regarding a Joint Venture to Collaborate on the Research, Development and Construction of an Advanced Nuclear Fuel Research and EXHIBIT 99.1 ASP Isotopes Inc. and its Subsidiary, Quantum Leap Energy LLC, enter into a Memorandum of Understanding with Fermi America Regarding a Joint Venture to Collaborate on the Research, Development and Construction of an Advanced Nuclear Fuel Research and Production Facility at the Planned 11GW HyperGrid Campus in Carson County, Texas - Fermi America is a private U.S. developer of the plan
August 14, 2025	EX-10.1	ASP Isotopes Inc. 2025 Inducement Equity Incentive Plan and forms of award agreement thereunder. Exhibit 10.1 ASP ISOTOPES INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN Exhibit 10.1 TABLE OF CONTENTS ASP Isotopes Inc. 2025 Inducement Equity Incentive Plan 1 1. Establishment, Purpose and term of Plan. 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction. 1 2.1 Definitions 1 2.2 Construction 8 3. Administration. 9 3.1 Administration by the Committee 9 3.2 Authorit
August 14, 2025	EX-10.3	Natrium Project Procurement Terms and Conditions – Enrichment Services by and between TerraPower, LLC and ASP Isotopes Inc., dated as of May 16, 2025 Exhibit 10.3 NATRIUM PROJECT PROCUREMENT TERMS AND CONDITIONS – ENRICHMENT SERVICES BY AND BETWEEN TERRAPOWER, llc AND ASP ISOTOPES INC. DATED AS OF MAY 16, 2025 Exhibit 10.3 TABLE OF CONTENTS 1. Definitions. 1 2. Work Authorization - Purchase Order. 6 2.1. Issuance of Purchase Order. 6 2.2. Base Line Item. 6 2.3. [Reserved]. 6 2.4. Price Basis. 6 3. Performance of the Work. 6 3.1. Statement of Wo
August 14, 2025	EX-10.4	HALEU Long-Term Supply Agreement by and between TerraPower, LLC and ASP Isotopes Inc., dated as of May 16, 2025 Exhibit 10.4 HALEU LONG-TERM SUPPLY AGREEMENT BY AND BETWEEN TERRAPOWER, llc AND ASP ISOTOPES INC. DATED AS OF MAY 16, 2025 Exhibit 10.4 TABLE OF CONTENTS 1. Definitions. 1 2. Work Authorization - Purchase Order. 7 2.1. Issuance of Purchase Order. 7 2.2. Base Line Item. 7 2.3. [Reserved]. 7 2.4. Price; Price Basis. 7 2.5. Quantity; Delivery Quantity Annual Estimate; Committed Quantity. 7 2.6. Addi
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
August 8, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N
August 8, 2025	EX-99.1	ASP Isotopes Inc. Announces Expected Commencement of Dual Listing on Johannesburg Stock Exchange EXHIBIT 99.1 ASP Isotopes Inc. Announces Expected Commencement of Dual Listing on Johannesburg Stock Exchange Washington, D.C., August 8, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided an upda
August 8, 2025	CB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 4) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 4) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exc
August 8, 2025	EX-99.5	Abridged Pre-listing Statement released by ASP Isotopes Inc. on the Stock Exchange News Service of the JSE Limited on August 8, 2025 for the purposes of complying with the JSE Listings Requirements in connection with the listing of ASP Isotopes Inc. shares of common stock on the Main Board of the Johannesburg Stock Exchange. EXHIBIT 99.5 ASP ISOTOPES INC. (Incorporated in the State of Delaware, United States of America) (Delaware file number 6228898) Ticker Symbol: NASDAQ: ASPI ISIN: US00218A1051 LEI: 6488WHV94BZ496OZ3219 JSE Share Code: ISO ("ASPI" or "the Company") SECONDARY LISTING OF ASPI ON THE MAIN BOARD OF THE JSE LIMITED ("JSE") AND ABRIDGED PRE-LISTING STATEMENT Unless otherwise stated, capitalised terms used
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 30, 2025	EX-99.1	Investor presentation regarding IsoBio dated July 2025. EXHIBIT 99.1
July 28, 2025	EX-99.1	ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment EXHIBIT 99.1 ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked
July 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 25, 2025	EX-99.1	Competition Commission of South Africa Approves the Offer by ASP Isotopes Inc. for Renergen Limited EXHIBIT 99.1 Competition Commission of South Africa Approves the Offer by ASP Isotopes Inc. for Renergen Limited Washington, D.C., July 25, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that
July 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 24, 2025	EX-1.1	Underwriting Agreement, dated as of July 23, 2025, by and between the Company and Cantor Fitzgerald & Co. as representative of the several underwriters named therein. EXHIBIT 1.1 7,500,000 Shares ASP Isotopes Inc. Common Stock UNDERWRITING AGREEMENT July 23, 2025 Cantor Fitzgerald & Co. As Representative of the Several Underwriters named in Schedule I attached hereto 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: ASP Isotopes Inc., a Delaware corporation (the “Company”), proposes to sell 7,500,000 shares (the “Stock”) of the Company’s common sto
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 24, 2025	424B5	7,500,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) File No. 333-286860 File No. 333-288894 PROSPECTUS SUPPLEMENT (to Prospectus dated May 30, 2025) 7,500,000 Shares Common Stock We are offering 7,500,000 shares of our common stock, par value $0.01 per share, at an offering price of $8.00 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On July 23, 2025, the l
July 24, 2025	424B5	7,500,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) File No. 333-286860 File No. 333-288894 PROSPECTUS SUPPLEMENT (to Prospectus dated May 30, 2025) 7,500,000 Shares Common Stock We are offering 7,500,000 shares of our common stock, par value $0.01 per share, at an offering price of $8.00 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On July 23, 2025, the l
July 24, 2025	EX-99.1	ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock EXHIBIT 99.1 ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock Washington, D.C., July 23, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of $8.00 per share to a single fundame
July 23, 2025	S-3MEF	As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No.
July 23, 2025	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) ASP Isotopes Inc.
July 17, 2025	EX-99.1	ASP Isotopes Inc. Announces Updates on the Progress of Commercial Production at its Three Enrichment Facilities in South Africa. EXHIBIT 99.1 ASP Isotopes Inc. Announces Updates on the Progress of Commercial Production at its Three Enrichment Facilities in South Africa. Washington, D.C., July 17, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple ind
July 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 11, 2025	EX-99.1	Shareholders of Renergen Limited Approve Proposed Acquisition by ASP Isotopes Inc. EXHIBIT 99.1 Shareholders of Renergen Limited Approve Proposed Acquisition by ASP Isotopes Inc. Washington, D.C., July 11, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that at a general mee
July 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
June 13, 2025	EX-99.1	Combined Circular to Renergen Shareholders in Relation to Scheme of Arrangement and Standby Offer EXHIBIT 99.1
June 13, 2025	EX-99.8	Joint Announcement released by Renergen and ASP Isotopes Inc. on the Stock Exchange News Service of the JSE Limited on June 12, 2025 regarding Distribution of Circular, Notice of General Meeting and Withdrawal of Cautionary Announcement. EXHIBIT 99.8 RENERGEN LIMITED (Incorporated in the Republic of South Africa) (Registration number 2014/195093/06) JSE and A2X Share code: REN ISIN: ZAE000202610 LEI:378900B1512179F35A69 Australian Business Number (ABN): 93 998 352 675 ASX Share code: RLT (“Renergen”) ASP ISOTOPES INC. (Incorporated in the State of Delaware, United States of America) (Delaware file number 6228898) Ticker Symbol: NA
June 13, 2025	CB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 3) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exc
June 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
June 11, 2025	EX-99.1	ASP Isotopes Inc. Enhances the Quantum Leap Energy LLC (QLE) Executive Leadership Team with the Appointment of Ryno Pretorius as Chief Executive Officer of QLE EXHIBIT 99.1 ASP Isotopes Inc. Enhances the Quantum Leap Energy LLC (QLE) Executive Leadership Team with the Appointment of Ryno Pretorius as Chief Executive Officer of QLE Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of i
June 4, 2025	EX-99.1	ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies EXHIBIT 99.1 ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies - Gadolinium-160 is a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapies. - Supply agreement is for four years’ supply of enriched Gd-160, commencing in 2026, with
June 4, 2025	EX-99.2	ASP Isotopes Inc. to host Investor Access Event in South Africa from June 16-18, 2025 EXHIBIT 99.2 ASP Isotopes Inc. to host Investor Access Event in South Africa from June 16-18, 2025 Washington, D.C., June 4, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will host a
June 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
June 2, 2025	424B5	7,518,797 Shares Common Stock Filed Pursuant to Rule 424(b)(5) File No. 333-286860 PROSPECTUS SUPPLEMENT (to Prospectus dated May 30, 2025) 7,518,797 Shares Common Stock We are offering 7,518,797 shares of our common stock, par value $0.01 per share, at an offering price of $6.65 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On May 30, 2025, the last reported sale pri
June 2, 2025	EX-1.1	Underwriting Agreement, dated as of June 2, 2025, by and between the Company and Cantor Fitzgerald & Co. as representative of the several underwriters named therein. EXHIBIT 1.1 7,518,797 Shares ASP Isotopes Inc. Common Stock UNDERWRITING AGREEMENT June 2, 2025 Cantor Fitzgerald & Co. As Representative of the Several Underwriters named in Schedule I attached hereto 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: ASP Isotopes Inc., a Delaware corporation (the “Company”), proposes to sell 7,518,797 shares (the “Stock”) of the Company’s common stoc
June 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
June 2, 2025	EX-99.1	ASP Isotopes Inc. Announces Pricing of $50 Million Underwritten Registered Direct Offering of Common Stock EXHIBIT 99.1 ASP Isotopes Inc. Announces Pricing of $50 Million Underwritten Registered Direct Offering of Common Stock Washington, D.C., June 2, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at a price of $6.65 per share to a single fundamen
May 29, 2025	EX-99.7	Announcement released by Renergen on the Stock Exchange News Service of the JSE Limited on May 28, 2025 regarding Distribution of Circular and Notice of General Meeting. EXHIBIT 99.7 RENERGEN LIMITED (Incorporated in the Republic of South Africa) (Registration number 2014/195093/06) JSE and A2X Share code: REN ISIN: ZAE000202610 LEI:378900B1512179F35A69 Australian Business Number (ABN): 93 998 352 675 ASX Share code: RLT (“Renergen”) DISTRIBUTION OF CIRCULAR AND NOTICE OF GENERAL MEETING Unless expressly defined otherwise, capitalised terms herein have the same me
May 29, 2025	CB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 2) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exc
May 29, 2025	EX-99.2	Circular to Renergen Shareholders in Relation to Shareholder Ratification Resolution EXHIBIT 99.2 THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION The definitions and interpretations commencing on page 6 of this Circular apply, unless the context clearly indicates otherwise, throughout this Circular, including this cover page. Action required: 1. This entire Circular is important and should be read with particular attention to the section entitled “Action required
May 29, 2025	EX-99.1	ASP Isotopes Issues Letter to Shareholders. EXHIBIT 99.1 ASP Isotopes Issues Letter to Shareholders. Washington, D.C., May 29, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and C
May 29, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 29, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 27, 2025	EX-99.1	RISK FACTORS EXHIBIT 99.1 RISK FACTORS Unless stated otherwise or dictated by context, all capitalized terms used herein but not defined shall have the meanings set forth in the Current Report on Form 8-K filed by ASP Isotopes Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission to which this risk factors document is attached (the “Form 8-K”). The following risks and uncert
May 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 27, 2025	EX-99.2	INDEX TO FINANCIAL STATEMENTS EXHIBIT 99.2 INDEX TO FINANCIAL STATEMENTS Page RENERGEN LIMITED Audited Consolidated Financial Statements Report of Independent Registered Public Accounting Firm (PCAOB ID 1368) 2 Consolidated Statement of Financial Position as of February 28, 2025 and February 29, 2024 3 Consolidated Statement of Profit or Loss and Other Comprehensive Loss for the years ended February 28, 2025 and February 29, 2
May 27, 2025	CORRESP	ASP Isotopes Inc. 601 Pennsylvania Avenue NW South Building, Suite 900 Washington, DC 20004 May 27, 2025 ASP Isotopes Inc. 601 Pennsylvania Avenue NW South Building, Suite 900 Washington, DC 20004 May 27, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: ASP Isotopes Inc. Registration Statement on Form S-3 File No. 333-286860 Acceleration Request Requested Date: Friday, May 30, 2025 Requested Time
May 27, 2025	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EXHIBIT 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements of ASP Isotopes Inc. (the “Company”) and Renergen Limited, a public company incorporated under the laws of the Republic of South Africa (“Renergen”), present the combination of the financial information of the Company and Renergen adjusted to give effec
May 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 22, 2025	EX-99.6	Merger Notice Form CC 4(1) and Merger Notice Form CC 4(2) were made publicly available in accordance with the requirements of Renergen’s home jurisdiction. EXHIBIT 99.6
May 22, 2025	EX-10.1	Loan Agreement, dated May 16, 2025, by and between QLE TP Funding SPE LLC, as borrower, and TerraPower, LLC, as lender. EXHIBIT 10.1 Execution Copy LOAN AGREEMENT BY AND BETWEEN QLE TP FUNDING SPE LLC, a Delaware limited liability company, AS BORROWER AND TERRAPOWER, LLC, a Delaware limited liability company AS LENDER Dated: May 16, 2025 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATIONS 5 Section 1.1 Definitions 5 Section 1.2 Singular and Plural Terms 16 Section 1.3 Accounting Principles 16 Section 1.4
May 22, 2025	CB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. 1) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exc
May 21, 2025	EX-99.4	The Press Release of ASP Isotopes Inc. dated May 20, 2025 and entitled “ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company” was made publicly available in the United States. EXHIBIT 99.4 ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company - Combining these two highly complementary businesses aims to create a global leader in the production of critical and strategically important materials, including electronic gases such as helium, various fluorinated products and iso
May 21, 2025	EX-99.3	Joint Firm Intention Announcement dated May 20, 2025 made by ASP Isotopes Inc. and Renergen was made publicly available in accordance with the requirements of Renergen’s home jurisdiction. EXHIBIT 99.3 RENERGEN LIMITED (Incorporated in the Republic of South Africa) (Registration number 2014/195093/06) JSE and A2X Share code: REN ISIN: ZAE000202610 LEI:378900B1512179F35A69 Australian Business Number (ABN): 93 998 352 675 ASX Share code: RLT ASP ISOTOPES INC. (Incorporated in the State of Delaware, United States of America) (Delaware file number 6228898) Ticker Symbol: NASDAQ: ASPI IS
May 21, 2025	CB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form CB TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM (AMENDMENT NO. ) Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to file this Form: Securities Act Rule 801 (Rights Offering) ☐ Securities Act Rule 802 (Exchange Offer) ☒ Exchange Act Rule 13e-4(h)(8) (Issuer Tender Offer) ☐ Exch
May 20, 2025	EX-99.1	Investor presentation dated May 20,2025. EXHIBIT 99.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
May 20, 2025	EX-2.1	Firm Intention Letter Agreement, dated May 20,2025, by and between ASP Isotopes Inc. and Renergen Limited. EXHIBIT 2.1 To: The Directors (Renergen Board) Renergen Limited Address: Sandton Gate, Second Floor, 25 Minerva Avenue, Glenadrienne, Sandton, Gauteng, 2196 Attention: The Chairman Dear Sirs FIRM INTENTION BY ASP ISOTOPES INC. (ASPI) TO MAKE AN OFFER TO ACQUIRE ALL ISSUED ORDINARY SHARES IN RENERGEN LIMITED (THE COMPANY) (ASPI AND THE COMPANY COLLECTIVELY REFERRED TO AS THE PARTIES, AND EACH A PAR
May 20, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 20, 2025	EX-99.2	ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company EXHIBIT 99.2 ASP Isotopes Inc. Announces an Agreement Relating to the Potential Acquisition of Renergen Limited Expected to Create a Global Critical Materials Company - Combining these two highly complementary businesses aims to create a global leader in the production of critical and strategically important materials, including electronic gases such as helium, various fluorinated products and iso
May 20, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
May 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
May 20, 2025	EX-10.1	Loan Agreement, dated May 19, 2025, by and among ASP Isotopes Inc., ASP Isotopes South Africa Proprietary Limited, as lender, and Renergen Limited, as borrower. EXHIBIT 10.1 TERM LOAN FACILITY AGREEMENT Between ASP ISOTOPES INCORPORATED and ASP ISOTOPES SOUTH AFRICA PROPRIETARY LIMITED and RENERGEN LIMITED Page 1 Table of Contents 1. PARTIES 3 2. BACKGROUND 3 3. DEFINITIONS 3 4. THE FACILITY 11 5. TERMINATION OF EXCLUSIVETY AGREEMENT 12 6. ADVANCECONDITIONS 12 7. ADVANCES 13 8. DRAWDOWNNOTICES 13 9. INTEREST 14 10. REPAYMENT OF INTEREST AND THE LOAN 14 11
May 20, 2025	EX-99.1	ASP Isotopes Inc. enters into Definitive Agreements with TerraPower including Loan Agreement for Construction of a HALEU Production Facility and Supply Agreements for HALEU EXHIBIT 99.1 ASP Isotopes Inc. enters into Definitive Agreements with TerraPower including Loan Agreement for Construction of a HALEU Production Facility and Supply Agreements for HALEU - Loan Agreement with TerraPower provides a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa. - Supply Agreement supports the supply of HALEU f
May 20, 2025	EX-99.3	RENERGEN LIMITED (Incorporated in the Republic of South Africa) (Registration number 2014/195093/06) JSE and A2X Share code: REN ISIN: ZAE000202610 Australian Business Number (ABN): 93 998 352 675 ASX Share code: RLT EXHIBIT 99.3 RENERGEN LIMITED (Incorporated in the Republic of South Africa) (Registration number 2014/195093/06) JSE and A2X Share code: REN ISIN: ZAE000202610 LEI:378900B1512179F35A69 Australian Business Number (ABN): 93 998 352 675 ASX Share code: RLT (“Renergen”) ASP ISOTOPES INC. (Incorporated in the State of Delaware, United States of America) (Delaware file number 6228898) Ticker Symbol: NA
May 15, 2025	NT 10-Q	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Expires: May 31, 2025 Estimated average burden Washington, D.
April 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41555 ASP Isotopes
April 30, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ASP Isotopes Inc.
April 30, 2025	EX-4.1	Form of indenture for senior debt securities and the related form of senior debt security. EXHIBIT 4.1 ASP ISOTOPES INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE One. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 11 SECTION 103. Form of Documents Delivered to Trustee 12 SECTION 104. Acts of Holders 12 SECTION 105. Notices, etc.,
April 30, 2025	EX-4.2	Form of indenture for subordinated debt securities and the related form of subordinated debt security. EXHIBIT 4.2 ASP ISOTOPES INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 101. Definitions 2 Section 102. Compliance Certificates and Opinions 11 Section 103. Form of Documents Delivered to Trustee 12 Section 104. Acts of Holders 12 Section 105. Notices,
April 30, 2025	S-3	As filed with the Securities and Exchange Commission on April 30, 2025 As filed with the Securities and Exchange Commission on April 30, 2025 Registration No.
April 30, 2025	EX-1.2	Equity Distribution Agreement, dated April 30, 2025, by and between ASP Isotopes Inc. and Canaccord Genuity LLC. EXHIBIT 1.2 ASP Isotopes Inc. Common Stock (par value $0.01 per share) $25,000,000 EQUITY DISTRIBUTION AGREEMENT April 30, 2025 Canaccord Genuity LLC 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 Ladies and Gentlemen: ASP Isotopes Inc., a Delaware corporation (the “Company”), confirms this agreement (this “Agreement”) with Canaccord Genuity LLC (the “Manager”) as follows: SECTION 1:
April 15, 2025	EX-99.1	ASP Isotopes Inc. Announces Changes in Boards of ASP Isotopes Inc. and Quantum Leap Energy LLC EXHIBIT 99.1 ASP Isotopes Inc. Announces Changes in Boards of ASP Isotopes Inc. and Quantum Leap Energy LLC - Highly respected South African Businessman, Mr Sipho Maseko, former CEO of Telkom SA Soc Ltd and MD of Vodacom SA, Has Joined the Board of Directors of ASP Isotopes Inc. - Dr. Hendrik Strydom, PhD, Chief Technology Officer of ASP Isotopes Inc., is transitioning from the Board of Directors
April 15, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N
April 9, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASP ISOTOPES INC.
April 9, 2025	S-8	As filed with the Securities and Exchange Commission on April 8, 2025 As filed with the Securities and Exchange Commission on April 8, 2025 Registration No.
April 1, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
April 1, 2025	EX-99.1	ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176 EXHIBIT 99.1 ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176 - Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Y
March 31, 2025	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 ASP Isotopes Inc. Subsidiaries of the Registrant Subsidiaries* Place of Incorporation ASP Isotopes Guernsey Limited (formerly, PDS-Photonica Holdings (Guernsey) Limited) Guernsey ASP Isotopes South Africa (Proprietary) Limited (formerly, PDS Photonica Holdings South Africa (PTY) Limited) South Africa Enlightened Isotopes (Pty) Ltd South Africa ASPI South Africa Asset Finance South Afr
March 31, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 ASP ISOTOPES INC. INSIDER TRADING POLICY As adopted by the Board of Directors as of December 9, 2024 Table of Contents Page Section 1. All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy 1 Section 2. Trading in ASP Isotopes Securities While in Possession of Material Nonpublic Information is Prohibited 1 Section 3. Trading Window 1 Sect
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41555 ASP Isotopes Inc. (Exact name of
March 31, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N
March 31, 2025	EX-99.1	ASP Isotopes Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results Webinar EX-99.1 2 aspiex991.htm PRESS RELEASE EXHIBIT 99.1 ASP Isotopes Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results Webinar Washington, D.C., March 31, 2025 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), announced that it will release its fourth quarter and fiscal year 2024 financial results after the close of financial markets today, March 31
March 31, 2025	EX-10.31	Non-Employee Director Compensation Policy adopted effective October 30, 2024. Exhibit 10.31 ASP Isotopes Inc. Non-Employee Director Compensation Policy Each individual who provides services to ASP Isotopes Inc. (the “Company”) as a member of the Board of Directors (the “Board”), other than any director who is employed by the Company or one of its subsidiaries (a “Covered Non-Employee Director”), will be entitled to receive the following amounts of compensation, subject to t
March 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N
March 27, 2025	EX-99.1	ASP Isotopes Inc. Commences Commercial Production of Enriched Silicon-28 at its Second Aerodynamic Separation Process (ASP) Enrichment Facility EXHIBIT 99.1 ASP Isotopes Inc. Commences Commercial Production of Enriched Silicon-28 at its Second Aerodynamic Separation Process (ASP) Enrichment Facility - Silicon-28 is an isotope that is believed to assist in enabling quantum computing and improving the performance of next generation semiconductors for artificial intelligence. - The Company expects to ship commercial product during 2Q25. - Th
February 26, 2025	EX-99.1	ASP Isotopes Inc. Commences Commercial Production of Enriched Carbon-14 at its First Aerodynamic Separation Process (ASP) Enrichment Facility EXHIBIT 99.1 ASP Isotopes Inc. Commences Commercial Production of Enriched Carbon-14 at its First Aerodynamic Separation Process (ASP) Enrichment Facility - The Company has commenced commercial production of enriched Carbon-14 at its first Aerodynamic Separation Process (ASP) enrichment facility. - The Company expects to ship commercial product around the middle of the year. - The Company previous
February 26, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
January 13, 2025	EX-99.1	ASP Isotopes Inc. Hosts Investor Access Event in South Africa Providing Updates on its Silicon-28, Ytterbium-176 and Carbon-14 Facilities EXHIBIT 99.1 ASP Isotopes Inc. Hosts Investor Access Event in South Africa Providing Updates on its Silicon-28, Ytterbium-176 and Carbon-14 Facilities - This week the Company welcomes a group of institutional investors from around the world to its facilities located in Pretoria, South Africa for a two-day investor access event. - During the investor access event, the Company intends to show the in
January 13, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
December 16, 2024	EX-99.1	ASP Isotopes Issues Letter to Shareholders. EXHIBIT 99.1 ASP Isotopes Issues Letter to Shareholders. Washington, D.C., Dec 16, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and C
December 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
December 13, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
December 13, 2024	EX-99.1	ASP Isotopes Inc. Responds To Short Seller “Report” EXHIBIT 99.1 ASP Isotopes Inc. Responds To Short Seller “Report” Washington, D.C., December 13, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today issued the following statement in response to short seller
December 2, 2024	EX-99.1	ASP Isotopes Inc. to host Investor Access Event in South Africa from January 14-16, 2025 EXHIBIT 99.1 ASP Isotopes Inc. to host Investor Access Event in South Africa from January 14-16, 2025 Washington, D.C., December 2, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will
December 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 27, 2024	EX-99.1	ASP Isotopes Inc. Responds to Short Seller Report EXHIBIT 99.1 ASP Isotopes Inc. Responds to Short Seller Report Washington, D.C., November 26, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today issued the following statement in response to a short seller
November 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
November 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
November 26, 2024	EX-99.1	ASP Isotopes Inc. Completes Construction and Starts the Commissioning of Silicon-28 Enrichment Facility EXHIBIT 99.1 ASP Isotopes Inc. Completes Construction and Starts the Commissioning of Silicon-28 Enrichment Facility - Construction of the Company’s Silicon-28 enrichment facility has been completed in line with previously communicated timelines. - Silicon-28 is an isotope that is believed to enable quantum computing and will likely improve the performance of next generation semiconductors for art
November 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 ASP Isotopes Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41555 87-2618235 (State or Other Jurisdiction of Incorporation) (Commission Fil
November 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
November 19, 2024	EX-10.1	Executive Employment Agreement by and between the Company and Heather Kiessling, dated June 10, 2024 (incorporated by reference to Exhibit 10.1 to the Form 10-Q filed on November 19, 2024). Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 10th day of June, 2024 by and between ASP Isotopes Inc., a Delaware corporation (the “Company”), and Heather Kiessling (“Executive”). As used herein, the “Effective Date” of this Agreement shall mean July 1, 2024 or such earlier date as mutually agreed to by Executive an
November 14, 2024	EX-99.1	ASP Isotopes Inc. enters into Memorandum of Understanding with the South African Nuclear Energy Corporation (Necsa) to collaborate on the research, development and construction of an Advanced Nuclear Fuel Production Facility EXHIBIT 99.1 ASP Isotopes Inc. enters into Memorandum of Understanding with the South African Nuclear Energy Corporation (Necsa) to collaborate on the research, development and construction of an Advanced Nuclear Fuel Production Facility - Necsa is an RSA state-owned company responsible for undertaking and promoting R&D in the field of nuclear energy. - MOU contemplates collaboration on the resear
November 14, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
November 14, 2024	NT 10-Q	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Estimated average burden Washington, D.
November 7, 2024	SC 13G/A	ASPI / ASP Isotopes Inc. / AK Jensen Investment Management Ltd - ASP ISOTOPES INC. Passive Investment SC 13G/A 1 p24-3238sc13ga.htm ASP ISOTOPES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ASP Isotopes Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 00218A105 (CUSIP Number) October 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr
November 4, 2024	EX-99.1	ASP Isotopes Announces Proposed Public Offering of Common Stock EXHIBIT 99.1 ASP Isotopes Announces Proposed Public Offering of Common Stock WASHINGTON, Oct. 31, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. ASP Isotopes intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number
November 4, 2024	424B5	2,395,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279857 Registration No. 333-282936 PROSPECTUS SUPPLEMENT (to Prospectus dated June 12, 2024) 2,395,000 Shares Common Stock We are offering 2,395,000 shares of our common stock, par value $0.01 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On October 30, 2024, the last reported sale pri
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 4, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 4, 2024	424B5	2,395,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279857 Registration No. 333-282936 PROSPECTUS SUPPLEMENT (to Prospectus dated June 12, 2024) 2,395,000 Shares Common Stock We are offering 2,395,000 shares of our common stock, par value $0.01 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On October 30, 2024, the last reported sale pri
November 4, 2024	EX-99.1	ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares EXHIBIT 99.1 ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares Washington, D.C., November 4, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced the closing of the previously announced underwritten public offering of shares of its common stock. ASP Isotopes sold 2,754,250 sh
November 4, 2024	EX-1.1	Underwriting Agreement, dated as of November 1, 2024, by and between the Company and the Underwriter. EXHIBIT 1.1 2,395,000 Shares ASP Isotopes Inc. Common Stock UNDERWRITING AGREEMENT November 1, 2024 Canaccord Genuity LLC As Representative of the Several Underwriters named in Schedule I attached hereto 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 Ladies and Gentlemen: ASP Isotopes Inc., a Delaware corporation (the “Company”), proposes to sell 2,395,000 shares (the “Firm Stock”) of
November 4, 2024	EX-99.2	ASP Isotopes Announces Pricing of Public Offering of Common Stock EXHIBIT 99.2 ASP Isotopes Announces Pricing of Public Offering of Common Stock WASHINGTON, Nov. 01, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”) today announced the pricing of the previously announced underwritten public offering of shares of its common stock. ASP Isotopes has agreed to sell an aggregate of 2,395,000 shares of its common stock at a publi
October 31, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) ASP Isotopes Inc.
October 31, 2024	424B5	SUBJECT TO COMPLETION, DATED OCTOBER 31, 2024 The information in this preliminary prospectus supplement is not complete and may be changed.
October 31, 2024	S-3MEF	As filed with the Securities and Exchange Commission on October 31, 2024 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No.
October 30, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
October 30, 2024	EX-99.1	ASP Isotopes Inc. enters into Term Sheet with TerraPower, LLC for Construction of a HALEU Production Facility EXHIBIT 99.1 October 30, 2024 ASP Isotopes Inc. enters into Term Sheet with TerraPower, LLC for Construction of a HALEU Production Facility - Term sheet contemplates preparation of definitive documentation pursuant to which TerraPower would provide funding for the construction of a uranium enrichment facility and would purchase HALEU after the expected completion of the facility. WASHINGTON, Oct.
October 21, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
October 17, 2024	EX-99.1	ASP Isotopes Inc. Enriches Ytterbium-176 During Commissioning Phase of First Quantum Enrichment Facility and Expects to Offer Highly Enriched Ytterbium-176 for Commercial Sale in 2025 EXHIBIT 99.1 ASP Isotopes Inc. Enriches Ytterbium-176 During Commissioning Phase of First Quantum Enrichment Facility and Expects to Offer Highly Enriched Ytterbium-176 for Commercial Sale in 2025 - The Company has accelerated the commissioning phase of its first Quantum Enrichment plant and produced the first semi-finished material of enriched Ytterbium- 176. - Commissioning phase was initially a
October 17, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
September 26, 2024	EX-99.1	ASP Isotopes Inc. Corporate Overview dated as of September 2024. EXHIBIT 99.1
September 26, 2024	EX-10.1	First Amendment to Quantum Leap Energy LLC 2024 Equity Incentive Plan. EXHIBIT 10.1 First Amendment To Quantum Leap Energy LLC 2024 Equity Incentive Plan Background A. Quantum Leap Energy LLC (the “Company”), maintains the Quantum Leap Energy LLC 2024 Equity Incentive Plan (the “Plan”). Capitalized terms used herein without definition shall have the meanings assigned to them in the Plan. B. The Plan was originally effective as of March 7, 2024, the date of the first
September 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fi
September 3, 2024	EX-99.1	ASP Isotopes Inc. Completes Construction Phase of Ytterbium-176 Enrichment Facility EXHIBIT 99.1 ASP Isotopes Inc. Completes Construction Phase of Ytterbium-176 Enrichment Facility - The Company has completed the construction phase of the first Quantum Enrichment plant for Ytterbium-176, approximately nine months ahead of the original schedule. - The Company expects to offer highly enriched Ytterbium-176 for commercial sale during 2025 after completion of the commissioning phase.
September 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
August 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
August 14, 2024	NT 10-Q	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Estimated average burden Washington, D.
July 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 15, 2024	EX-99.1	ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares EXHIBIT 99.1 ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares Washington, D.C., July 15, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced the closing of the previously announced underwritten public offering of shares of its common stock. ASP Isotopes sold 13,800,000 shar
July 12, 2024	EX-99.2	ASP Isotopes Announces Pricing of Public Offering of Common Stock EXHIBIT 99.2 ASP Isotopes Announces Pricing of Public Offering of Common Stock Washington, D.C., July 12, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”) today announced the pricing of the previously announced underwritten public offering of shares of its common stock. ASP Isotopes has agreed to sell an aggregate of 12,000,000 shares of its common stock at
July 12, 2024	EX-1.1	Underwriting Agreement, dated as of July 12, 2024, by and between the Company and the Underwriter. EXHIBIT 1.1 12,000,000 Shares ASP Isotopes Inc. Common Stock UNDERWRITING AGREEMENT July 12, 2024 Canaccord Genuity LLC As Representative of the Several Underwriters named in Schedule I attached hereto 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 Ladies and Gentlemen: ASP Isotopes Inc., a Delaware corporation (the “Company”), proposes to sell 12,000,000 shares (the “Firm Stock”) of
July 12, 2024	EX-99.1	ASP Isotopes Announces Proposed Public Offering of Common Stock EXHIBIT 99.1 ASP Isotopes Announces Proposed Public Offering of Common Stock Washington, D.C., July 11, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company") today announced that it has commenced an underwritten public offering of shares of its common stock. ASP Isotopes intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the
July 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
July 12, 2024	424B5	12,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279857 PROSPECTUS SUPPLEMENT (to Prospectus dated June 12, 2024) 12,000,000 Shares Common Stock We are offering 12,000,000 shares of our common stock, par value $0.01 per share. Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On July 11, 2024, the last reported sale price of shares of our common st
July 11, 2024	424B5	SUBJECT TO COMPLETION, DATED JULY 11, 2024 The information in this preliminary prospectus supplement is not complete and may be changed.
July 1, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 ASP Isotopes
July 1, 2024	CORRESP	ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 July 1, 2024 ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 July 1, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Kristin Lochhead Li Xiao Re: ASP Isotopes Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-41555 Dear Ms. Lochhead
June 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
June 13, 2024	EX-99.1	ASP Isotopes Inc. Enhances Executive Leadership Team with the Appointment of Heather Kiessling as Chief Financial Officer EXHIBIT 99.1 ASP Isotopes Inc. Enhances Executive Leadership Team with the Appointment of Heather Kiessling as Chief Financial Officer Washington, D.C., June 13, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries
June 13, 2024	EX-10.1	ASP Isotopes Inc. 2024 Inducement Equity Incentive Plan and forms of award agreement thereunder (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 13, 2024). EXHIBIT 10.1 ASP ISOTOPES INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN TABLE OF CONTENTS ASP Isotopes Inc. 2024 Inducement Equity Incentive Plan 1 1. Establishment, Purpose and term of Plan. 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction. 1 2.1 Definitions 1 2.2 Construction 9 3. Administration. 9 3.1 Administration by the Committee 9 3.2 Authority of Officers
June 12, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASP ISOTOPES INC.
June 12, 2024	S-8	As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration No.
June 12, 2024	EX-99.1	ASP Isotopes Inc. 2024 Inducement Equity Incentive Plan and forms of award agreement thereunder EXHIBIT 99.1 ASP ISOTOPES INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN TABLE OF CONTENTS ASP Isotopes Inc. 2024 Inducement Equity Incentive Plan 1 1. Establishment, Purpose and term of Plan. 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction. 1 2.1 Definitions 1 2.2 Construction 9 3. Administration. 9 3.1 Administration by the Committee 9 3.2 Authority of Officers
June 12, 2024	S-8	As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration No.
June 12, 2024	424B5	Common Stock Preferred Stock Debt Securities Filed Pursuant to Rule 424(b)(5) File No. 333-279857 PROSPECTUS $50,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may from time to time offer and sell any securities described in this prospectus, either individually or in combination with other securities, in one or more offerings of up to $50.0 million in aggregate initial offering price. This prospectus provides a genera
June 12, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASP ISOTOPES INC.
June 10, 2024	CORRESP	ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 June 10, 2024 ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 June 10, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: ASP Isotopes Inc. Registration Statement on Form S-3 File No. 333-279857 Acceleration Request Requested Date: Wednesday, June 12, 2024 Requested Time: 4:00 P.M. Ea
June 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Num
June 6, 2024	EX-10.1	Convertible Note Purchase Agreement (including Form of Convertible Promissory QLE Note), dated as of June 5, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on June 6, 2024). EXHIBIT 10.1 Execution Copy CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (this “Agreement”), dated as of June 5, 2024, is entered into among Quantum Leap Energy LLC, a Delaware limited liability company (the “Company”), and the persons and entities (each individually a “Purchaser,” and collectively, the “Purchasers”) named on the Schedule of Purchasers attached here
June 6, 2024	EX-10.2	Registration Rights Agreement, dated as of June 5, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein (incorporated by reference to Exhibit 10.2 to the Form 8-K filed on June 6, 2024). EXHIBIT 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 5, 2024 among Quantum Leap Energy LLC, a Delaware limited liability company (the “Company”), and the persons identified on Schedule A hereto (collectively, the “Investors” and, each individually, an “Investor”). WHEREAS, the Company and the Investors a
May 31, 2024	S-3	As filed with the Securities and Exchange Commission on May 31, 2024 As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.
May 31, 2024	EX-4.1	Form of indenture for senior debt securities and the related form of senior debt security. EXHIBIT 4.1 ASP ISOTOPES INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE One. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 11 SECTION 103. Form of Documents Delivered to Trustee 12 SECTION 104. Acts of Holders 12 SECTION 105. Notices, etc.,
May 31, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) ASP Isotopes Inc.
May 31, 2024	EX-4.2	Form of indenture for subordinated debt securities and the related form of subordinated debt security. EXHIBIT 4.2 ASP ISOTOPES INC. ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE. - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 101. Definitions 2 Section 102. Compliance Certificates and Opinions 11 Section 103. Form of Documents Delivered to Trustee 12 Section 104. Acts of Holders 12 Section 105. Notices,
May 22, 2024	424B3	1,225,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) File No. 333-279267 PROSPECTUS 1,225,000 Shares of Common Stock This prospectus covers the resale, from time to time, by the selling stockholder identified in this prospectus, or, the selling stockholder, of up to 1,225,000 shares of common stock, par value $0.01 per share, of ASP Isotopes Inc. (“common stock”), issuable upon the exercise of warrants held by the se
May 17, 2024	CORRESP	ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 May 17, 2024 ASP Isotopes Inc. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 May 17, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: ASP Isotopes Inc. Registration Statement on Form S-3 File No. 333-279267 Acceleration Request Requested Date: Tuesday, May 21, 2024 Requested Time: 4:00 P.M. Easter
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
May 9, 2024	S-3	As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.
May 9, 2024	EX-FILING FEES	Calculation of Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ASP Isotopes Inc.
April 29, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 ASP Isotopes
April 10, 2024	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 ASP Isotopes Inc. Subsidiaries of the Registrant Subsidiaries* Place of Incorporation ASP Isotopes Guernsey Limited (formerly, PDS-Photonica Holdings (Guernsey) Limited) Guernsey ASP Isotopes South Africa (Proprietary) Limited (formerly, PDS Photonica Holdings South Africa (PTY) Limited) South Africa Enriched Energy LLC Delaware, U.S. ASP Isotopes UK Ltd England & Wales Enlightened Is
April 10, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 ASP Isotopes Inc. (Exact name of
April 10, 2024	EX-97.1	Policy Relating to Recovery of Erroneously Awarded Compensation, effective October 2, 2023. EXHIBIT 97.1 ASP ISOTOPES INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION 1. INTRODUCTION ASP Isotopes Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circumstances. This Policy is effective as of Oc
April 10, 2024	EX-3.2	Amended and Restated Bylaws. EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF ASP ISOTOPES INC. Effective as of April 5, 2024 ARTICLE I CORPORATE OFFICES 1.1 Registered Office. The address of the registered office of ASP Isotopes Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporation, as the same may be amended
April 10, 2024	EX-4.1	Exhibit 4.1 EXHIBIT 4.1 DESCRIPTION OF CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of ASP Isotopes Inc. (“we,” “us” and “our”) is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Amended and Restated Certificate of Incorporation (“Certificate of Incorporat
April 9, 2024	EX-4.1	Warrant issued to Armistice Capital Master Fund Ltd. dated April 10, 2024 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 9, 2024). EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 9, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
April 9, 2024	EX-10.1	Form of Warrant Inducement Agreement by and between ASP Isotopes Inc. and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 9, 2024). EXHIBIT 10.1 ASP ISOTOPES INC. 1101 Pennsylvania Avenue NW, Suite 300 Washington, DC 20004 April 9, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: ASP Isotopes Inc., a Delaware corporation (the “Company”), is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants (“New Warr
March 29, 2024	NT 10-K	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2025 Estimated average burden Washington, D.
February 29, 2024	EX-99.4	LICENCE AGREEMENT ASP Isotopes UK Limited Quantum Leap Energy LLC Quantum Leap Energy Limited EXHIBIT 99.4 LICENCE AGREEMENT between ASP Isotopes UK Limited and Quantum Leap Energy LLC and Quantum Leap Energy Limited INDEX NO CLAUSE HEADING PAGE 1 DEFINITIONS AND INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 5 2 GRANT OF LICENCE 6 3 EXCLUSIVITY AND LICENCE RESTRICTIONS 6 4 DURATION 7 5 INTELLECTUAL PROPERTY RIGHTS AND IMPROVEMENTS 7 5.1 Intellectual Property Rights 7 5.2 Improvemen
February 29, 2024	EX-99.1	2 EXHIBIT 99.1 February 16, 2024 ASP Isotopes Inc. Provides Update on Plans to Spin-Out its Wholly Owned Subsidiary, Quantum Leap Energy - ASP Isotopes plans to spin a portion of Quantum Leap Energy’s common equity to ASP Isotopes' stockholders as of a future record date, in a tax efficient manner. - ASP Isotopes licenses rights to technology related to the enrichment of nuclear fuels to Quantum Lea
February 29, 2024	EX-10.2	Registration Rights Agreement, dated as of February 29, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein. EXHIBIT 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 29, 2024 among Quantum Leap Energy LLC, a Delaware limited liability company (the “Company”), and the persons identified on Schedule A hereto (collectively, the “Investors” and, each individually, an “Investor”). WHEREAS, the Company and the Invest
February 29, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
February 29, 2024	EX-99.2	2 EXHIBIT 99.2 February 18, 2024 ASP Isotopes Inc. Announces Proposed Offering of Convertible Notes by Quantum Leap Energy WASHINGTON, Feb. 18, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, announce
February 29, 2024	EX-10.1	Convertible Note Purchase Agreement (including Form of Convertible Promissory QLE Note), dated as of February 29, 2024, by and among Quantum Leap Energy LLC and the Purchasers listed therein. EXHIBIT 10.1 Execution Copy CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (this “Agreement”), dated as of February 29, 2024, is entered into among Quantum Leap Energy LLC, a Delaware limited liability company (the “Company”), and the persons and entities (each individually a “Purchaser,” and collectively, the “Purchasers”) named on the Schedule of Purchasers attached
February 29, 2024	EX-99.5	EPC Services Framework Agreement EXHIBIT 99.5 Execution Copy EPC Services Framework Agreement THIS EPC SERVICES FRAMEWORK AGREEMENT (this “Agreement”), dated as of February 16, 2024, is entered into by and between ASP Isotopes Inc., a Delaware corporation (“ASPI”), and Quantum Leap Energy LLC, a Delaware limited liability company (“QLE”). ASPI and QLE are sometimes referred to individually as a “Party” and collectively as the “Pa
February 29, 2024	EX-99.3	2 EXHIBIT 99.3 ASP Isotopes Inc. Announces Signing of Purchase Agreement for Offering of Convertible Notes by Quantum Leap Energy. Washington, D.C., February 29, 2024 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple in
February 29, 2024	EX-10.3	Quantum Leap Energy LLC 2024 Equity Incentive Plan. EXHIBIT 10.3 QUANTUM LEAP ENERGY LLC 2024 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Qunatum Leap Energy LLC 2024 Equity Incentive Plan 1 1. Establishment, Purpose and term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 9 3. Administration 9 3.1 Administration by the Committee 9 3.2 Authority of Officers 10 3.3 Admin
January 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
December 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 30, 2023	424B3	The date of this prospectus is November 28, 2023 Filed pursuant to Rule 424(b)(3) Registration No. 333-275686 This prospectus relates to the offer and sale from time to time by certain of our stockholders identified in this prospectus or their permitted transferees (the “Selling Stockholders”) of up to an aggregate of 10,150,517 shares (the “Registrable Securities”) of common stock, par value $0.01 per share (the “Common Stock”), of ASP Isotopes
November 27, 2023	EX-99.1	1 EXHIBIT 99.1 November 27, 2023 ASP Isotopes Inc. Enters Into Memorandum of Understanding (MOU) With Second US-based Small Modular Reactor (SMR) Company To Supply High Assay Low Enriched Uranium (HALEU) -The MOU outlines terms for a proposed collaboration on the development of a facility for producing HALEU, a vital nuclear fuel of the future. This collaboration includes a plan for the SMR company
November 27, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fil
November 24, 2023	CORRESP	November 24, 2023 November 24, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 21, 2023	EX-FILING FEES	Filing fee table. EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) ASP Isotopes Inc.
November 21, 2023	S-1	As filed with the Securities and Exchange Commission on November 21, 2023 As filed with the Securities and Exchange Commission on November 21, 2023 File No.
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
November 3, 2023	SC 13G	ASPI / ASP Isotopes Inc / AK Jensen Investment Management Ltd - ASP ISOTOPES INC. Passive Investment SC 13G 1 p23-1662sc13g.htm ASP ISOTOPES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ASP Isotopes Inc. (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 00218A105 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat
November 3, 2023	EX-10.1	Share Purchase Agreement, dated October 30, 2023, by and between ASP Isotopes Inc., as purchaser, and Nucleonics Imaging Proprietary Limited, as seller, relating to the purchase and sale of ordinary shares of Pet Labs Pharmaceuticals Proprietary Limited. EXHIBIT 10.1 Execution Version Share Purchase Agreement ASP ISOTOPES INC NUCLEONICS IMAGING PROPRIETARY LIMITED Dated October 30, 2023 DLA Piper Advisory Services Proprietary Limited is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. A list of offices and regulatory information can be found at dlapiper.com Contents PARTIES 1 BACKGROUND 1 AGREED
November 3, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
November 3, 2023	EX-99.1	ASP Isotopes Inc. Enters Strategic Relationship With PET Labs Pharmaceuticals for the Distribution of Medical Isotopes EXHIBIT 99.1 ASP Isotopes Inc. Enters Strategic Relationship With PET Labs Pharmaceuticals for the Distribution of Medical Isotopes October 29, 2023 • 7:35 PM EDT WASHINGTON, Oct. 29, 2023 (GLOBE NEWSWIRE) - ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotope
November 2, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
October 23, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
October 12, 2023	EX-10.2	Form of Registration Rights Agreement by and between ASP Isotopes Inc. and the purchasers named therein (October 2023 private placement of shares). EXHIBIT 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [•], 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pur
October 12, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
October 12, 2023	EX-99.1	ASP Isotopes Announces Private Placement of Approximately $8 Million Shares of Common Stock, Priced "At the Market" Under NASDAQ Rules EXHIBIT 99.1 ASP Isotopes Announces Private Placement of Approximately $8 Million Shares of Common Stock, Priced "At the Market" Under NASDAQ Rules Investors Include Well Known Uranium and Critical Resource Investor Tees River, through its Tees River Critical Resources Fund and Members of the Board WASHINGTON, Oct. 09, 2023 (GLOBE NEWSWIRE) - ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company",
October 12, 2023	EX-10.1	Form of Securities Purchase Agreement by and between ASP Isotopes Inc. and the purchasers named therein (October 2023 private placement of shares). EXHIBIT 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October [•], 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms a
October 3, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
October 3, 2023	EX-99.1	ASP Isotopes Issues Letter to Shareholders. EXHIBIT 99.1 ASP Isotopes Issues Letter to Shareholders. Washington, D.C., October 3, 2023 (GLOBE NEWSWIRE) - ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Ma
October 3, 2023	EX-99.2	Corporate Overview Presentation of ASP Isotopes Inc. dated October 2023 EXHIBIT 99.2
September 28, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fi
September 28, 2023	EX-99.1	ASP Isotopes Inc. Enters Into Memorandum of Understanding With a Small Modular Reactor Company To Supply High Assay Low Enriched Uranium (HALEU) EXHIBIT 99.1 ASP Isotopes Inc. Enters Into Memorandum of Understanding With a Small Modular Reactor Company To Supply High Assay Low Enriched Uranium (HALEU) ASP Isotopes Inc. Enters Into Discussions With Four Further Additional Customers To Supply HALEU and Creates New Subsidiary Focused on Enriching Uranium for the Production of Advanced Nuclear Fuels -Both the Memorandum of Understanding (MOU)
September 25, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission Fi
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ASP Isotopes Inc. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
June 27, 2023	EX-99.1	1 EXHIBIT 99.1 ASP Isotopes Inc. Secures $9 Million Supply Contract with US Customer for Highly Enriched Isotopes Approximately $900,000 to be Recorded in 3Q23, with Deliveries Anticipated to Begin in Q1 of 2024. ASP Isotopes Inc. NASDAQ: ASPI (“ASPI,” the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple
June 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
June 12, 2023	EX-99.1	June 2023 ASP Isotopes Inc. Investor Presentation EXHIBIT 99.1
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Nu
June 12, 2023	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File
June 12, 2023	EX-99.1	June 2023 ASP Isotopes Inc. Investor Presentation EXHIBIT 99.1
May 19, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41555 ASP Isotopes Inc.
May 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 001-41555 Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 001-41555 Notification of Late Filing (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Re
May 10, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File Numb
April 12, 2023	CORRESP	ASP ISOTOPES INC. 433 Plaza Real, Suite 275 Boca Raton, Florida 33432 (561) 709-3034 ASP ISOTOPES INC. 433 Plaza Real, Suite 275 Boca Raton, Florida 33432 (561) 709-3034 April 12, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ASP Isotopes Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-271137) Ladies and Gentlemen: In accordance with Rule 461 under the Securities A
April 5, 2023	S-1	As filed with the Securities and Exchange Commission on April 5, 2023. As filed with the Securities and Exchange Commission on April 5, 2023. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASP Isotopes Inc. (Exact name of Registrant as specified in its charter) Delaware 2890 87-2618235 (State or other jurisdiction of incorporation or organization) (Primary Stand
April 5, 2023	EX-10.23	Registration Rights Agreement dated March 14, 2023 (private placement of shares and warrants). EXHIBIT 10.23 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [ ], 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreemen
April 5, 2023	EX-10.25	Contract between Bricem Science and Technology Co and Klydon (Pty) Ltd EXHIBIT 10.25
April 5, 2023	EX-10.22	Securities Purchase Agreement dated March 14, 2023 (private placement of shares and warrants). EXHIBIT 10.22 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 14, 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
April 5, 2023	EX-4.2	Common Stock Purchase Warrant dated March 17, 2023. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 5, 2023	EX-10.27	Release Agreement, dated March 23, 2023 between Revere Securities LLC and ASP Isotopes Inc. EXHIBIT 10.27
April 5, 2023	EX-10.24	Memorandum of Understanding CC Nuclear Inc dated September 19, 2022. EXHIBIT 10.24
April 5, 2023	EX-21.1	List of Subsidiaries of the Registrant. EXHIBIT 21.1 ASP Isotopes Inc. Subsidiaries of the Registrant Subsidiaries* Place of Incorporation ASP Isotopes Guernsey Limited (formerly, PDS-Photonica Holdings (Guernsey) Limited) Guernsey ASP Isotopes South Africa (Proprietary) Limited (formerly, PDS Photonica Holdings South Africa (PTY) Limited) South Africa Enriched Energy LLC Delaware, U.S. ASP Isotopes UK Ltd England & Wales Enlightened Is
April 5, 2023	EX-FILING FEES	Filing fee table. EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-1 (Form Type) ASP Isotopes Inc.
April 5, 2023	EX-10.26	Assignment of Contract between Bricem Science and Technology Co and Klydon (Pty) Ltd. EXHIBIT 10.26
April 5, 2023	EX-4.3	Placement Agent Common Stock Purchase Warrant dated March 17, 2023. EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 5, 2023	EX-1.1	Underwriting Agreement H.C. Wainwright. EXHIBIT 1.1 February DATE], 2023 STRICTLY CONFIDENTIAL ASP Isotopes Inc. 433 Plaza Real, Suite 275 Boca Raton, Florida 33432 Attn: Paul E. Mann, Chairman and Chief Executive Officer Dear Mr. Mann: This letter agreement (this “Agreement”) constitutes the agreement between ASP Isotopes Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive un
March 31, 2023	EX-10.20	Acknowledgement of Debt Agreement between ASP Isotopes South Africa (Proprietary) Limited and Klydon (Proprietary) Limited dated November 30, 2022 EXHIBIT 10.20 Acknowledgement of Debt ASP Isotopes South Africa Proprietary Limited Klydon Proprietary Limited Dated 2022 DLA Piper Advisory Services Proprietary Limited is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. A list of offices and regulatory information can be found at dlapiper.com Contents PARTIES 1 BACKGROUND 1 AGREED TERMS 2 1 De
March 31, 2023	EX-10.18	Amended Advisory Agreement between the registrant and ChemBridges, LLC, dated December 12, 2022. EXHIBIT 10.18
March 31, 2023	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 ASP Isotopes Inc. Subsidiaries of the Registrant Subsidiaries* Place of Incorporation ASP Isotopes Guernsey Limited (formerly, PDS-Photonica Holdings (Guernsey) Limited) Guernsey ASP Isotopes South Africa (Proprietary) Limited (formerly, PDS Photonica Holdings South Africa (PTY) Limited) South Africa Enriched Energy LLC Delaware, U.S. ASP Isotopes UK Ltd England & Wales Enlightened Is
March 31, 2023	EX-10.19	Amended Executive Employment Agreement between the registrant and Paul Mann effective December 20, 2022. EXHIBIT 10.19
March 31, 2023	EX-10.21	Deed of Security Agreement between ASP Isotopes South Africa (Proprietary) Limited and Klydon (Proprietary) Limited dated November 30, 2022 EXHIBIT 10.21 EXECUTION VERSION 25 November 2022 Deed of Security Klydon Proprietary Limited (as Pledgor) ASP Isotopes South Africa Proprietary Limited (as Pledgee) DLA Piper Advisory Services Proprietary Limited is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. A list of offices and regulatory information can be found at dlapiper.com Contents
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 ASP Isotopes Inc. (Exact name of
March 17, 2023	EX-4.1	Form of Common Warrant EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 17, 2023	EX-4.2	Form of PA Warrant EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
March 17, 2023	EX-99.2	ASP Isotopes Announces Closing of $5 Million Private Placement EXHIBIT 99.2 ASP Isotopes Announces Closing of $5 Million Private Placement BOCA RATON, FL / ACCESSWIRE / March 17, 2023 / ASP Isotopes Inc. NASDAQ: ASPI (“ASPI”, the “Company”, “us”, “we” or “our”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced the closing of its previously announ
March 17, 2023	EX-10.1	Form of Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 14, 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set
March 17, 2023	EX-99.1	ASP Isotopes Announces $5 Million Private Placement EXHIBIT 99.1 ASP Isotopes Announces $5 Million Private Placement BOCA RATON, FL / ACCESSWIRE / March 15, 2023 / ASP Isotopes Inc. NASDAQ: ASPI (“ASPI”, the “Company”, “us”, “we” or “our”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that it has entered into a definitive agreement
March 17, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N
March 17, 2023	EX-10.2	Form of Registration Rights Agreement EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 14, 2023, between ASP Isotopes Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agre
March 14, 2023	EX-99.1	433 Plaza Real, Suite 275, Boca Raton, FL. 33432 ASP Isotopes Announces Letter to Stockholders EXHIBIT 99.1 433 Plaza Real, Suite 275, Boca Raton, FL. 33432 ASP Isotopes Announces Letter to Stockholders BOCA RATON, FL / ACCESSWIRE / March 13, 2023 / ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”, the “Company”, “us”, “we” or “our”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today announced a let
March 14, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 ASP ISOTOPES INC. (Exact name of registrant as specified in its charter) Delaware 001-41555 87-2618235 (State or other jurisdiction of incorporation) (Commission File N

ASPI / ASP Isotopes Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings

ZA:ISO	ZAR 14,775.00
DE:W62